The New York Gaming Commission has reported further positives for harness racing trainers in testing samples for the Class 2 Drug Glaucine.
Trainers Mark Ford, Nick Surick, Daniel Renaud and Milo Zdjelar have all been given notices that horses they raced came up positive for this drug.
This follows last week's announcement that Ron Burke and Julie Miller were hit with similar drug violations.
Please note, that these are only accusations, and that each of these licensees has a right to due process pursuant to New York law and regulations.
Extract from Wikipedia
Glaucine is an alkaloid found in several different plant species in the Papaveraceae family such as Glaucium flavum, Glaucium oxylobum and Corydalis yanhusuo, and in other plants like Croton lechleri in the family Euphorbiaceae.
It has bronchodilator and antiinflammatory effects, acting as a PDE4 inhibitor and calcium channel blocker, and is used medically as an antitussive in some countries. Glaucine may produce side effects such assedation, fatigue, and a hallucinogenic effect characterised by colourful visual images, and has been detected as a novel psychoactive drug.
Mechanism of Action
Glaucine binds to the benzothiazepine site on L-type Ca2+-channels, thereby blocking calcium ion channels in smooth muscle like the human bronchus. Glaucine has no effect on intracellular calcium stores, but rather, does not allow the entry of Ca2+ after intracellular stores have been depleted.[5] Ca2+ influx is a vital component in the process of muscular contraction, and the blocking of this influx therefore reduces the ability of the muscle to contract. In this way, glaucine can prevent smooth muscle from contracting, allowing it to relax.
Glaucine has also been demonstrated to be a dopamine receptor antagonist, favoring D1 and D1-like receptors. It is also a non-competitive selective inhibitor of PDE4 in human bronchial tissue and granulocytes. PDE4 is an isoenzyme that hydrolyzes cyclic AMP to regulate human bronchial tone (along with PDE3). Yet as a PDE4 inhibitor, glaucine possesses very low potency.
Harnesslink Media